Written by the Cleared Peptides Research Desk, the editorial desk of Cleared Wellness Group LLC. This is not a personal profile of a physician or a scientist, and it is not a fictional author. The checking method is public on the research desk page. Last reviewed October 2026.
Research use only. MOTS-c and tesamorelin are separate laboratory materials. Neither is a drug, food, cosmetic, or dietary supplement. Neither is FDA-approved on the strength of this page. Neither is for human or veterinary administration. This page does not give a dose or a method of administration. The papers below describe their own test articles.
Why this catalog does not sell a MOTS-c and tesamorelin blend
Buyers sometimes ask for one vial that mixes MOTS-c and tesamorelin. This catalog does not have that product. The two peptides are not two strengths of one pathway. Putting them in one sentence, or in one vial, creates a third test article that neither paper studied.
Two mechanisms
Lee, Zeng, Drew, Sallam, and colleagues described MOTS-c in 2015 as a 16-residue peptide encoded by a short open reading frame in mitochondrial 12S rRNA. In their paper, the cellular action they report runs through the folate cycle and de novo purine synthesis toward AMPK, and the experiments that followed were in cells and in mice. That paper is PubMed 25738459, DOI 10.1016/j.cmet.2015.02.009. The catalog sequence for the separate MOTS-c material is Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, CAS 1627580-64-6. A synthetic vial is not a peptide that a mitochondrion just translated. The mass on the certificate has to match the synthetic 16-mer.
Falutz, Allas, Blot, and colleagues reported tesamorelin in 2007 as a growth hormone-releasing factor analogue given to adults with HIV and an accumulation of abdominal fat. The trial’s own endpoint was visceral adipose tissue on computed tomography, and IGF-I rose in the tesamorelin arm. That paper is PubMed 18057338, DOI 10.1056/NEJMoa072375. Tesamorelin in this catalog is specified as a 44-residue GHRH analogue with an N-terminal trans-3-hexenoyl group, code TH9507, CAS 218949-48-5. The NEJM article is about a sponsor’s finished drug product in a human protocol. It is not a certificate for the lyophilized research material, and this page does not repeat the trial dose.
One peptide, in the Lee paper, is a mitochondrial signal. The other, in the Falutz paper, is a GHRH-receptor analogue acting on the pathway that raises growth hormone and IGF-I. They do not share a sequence, a CAS number, a receptor, or a paper. Ipamorelin is a third, different case: Raun and colleagues described it as a ghrelin-receptor-pathway secretagogue, not as a GHRH analogue. That comparison is on the ipamorelin and tesamorelin guides.
What a blend would have to prove
A vial that contained both sequences would need two identity results, one for each mass, and a statement of how much of each component was present. Lee 2015 did not test that mixture. Falutz 2007 did not test that mixture. No sentence of the form “the blend did what the two papers did” can be checked, because there is no such paper in the notes above.
The mitochondrial combination this catalog does sell is a research set of MOTS-c and SS-31, shipped as two materials. SS-31 is a tetrapeptide discussed by Birk and colleagues as a cardiolipin-binding compound, which is a different mechanism again from tesamorelin. See MOTS-c + SS-31, MOTS-c, and tesamorelin.
How to verify this page
- Open both papers and confirm the author surnames.
- Confirm MOTS-c in Lee is 16 residues from mitochondrial 12S rRNA, and that tesamorelin in Falutz is a GHRH analogue studied as a drug in people with HIV.
- Match CAS 1627580-64-6 and CAS 218949-48-5 to the two product tables. A single mass cannot confirm both.
- Treat the clinical endpoint in the NEJM paper as belonging to that trial. Lot purity stays on each lot’s certificate of analysis.
